Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Downgraded by BidaskClub to Hold

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Monday, July 24th.

Several other equities analysts have also commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Citigroup Inc. increased their price objective on shares of Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, June 9th. Jefferies Group LLC reiterated a “buy” rating and set a $148.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, June 30th. Wells Fargo & Company reiterated a “market weight” rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $141.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $136.90.

Shares of Zimmer Biomet Holdings (NYSE ZBH) opened at 111.70 on Monday. The firm has a 50-day moving average of $124.93 and a 200 day moving average of $121.26. The company has a market capitalization of $22.59 billion, a P/E ratio of 31.81 and a beta of 1.20. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by $0.02. The company had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business’s revenue was up 1.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.02 earnings per share. On average, analysts anticipate that Zimmer Biomet Holdings will post $8.24 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Downgraded by BidaskClub to Hold” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/12/zimmer-biomet-holdings-inc-nysezbh-downgraded-to-hold-at-bidaskclub-updated-updated.html.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Enterprise Financial Services Corp increased its position in shares of Zimmer Biomet Holdings by 0.3% in the second quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock worth $340,000 after buying an additional 9 shares during the last quarter. Alpha Windward LLC increased its position in shares of Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock worth $202,000 after buying an additional 18 shares during the last quarter. Sandy Spring Bank increased its position in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares during the last quarter. Parkside Financial Bank & Trust increased its position in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares during the last quarter. Finally, Cleararc Capital Inc. increased its position in shares of Zimmer Biomet Holdings by 0.5% in the first quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock worth $598,000 after buying an additional 25 shares during the last quarter. 83.62% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit